(Portland, Ore.) – Oregon Bioscience Association participated in the 2019 BIO Legislative Day Fly-In with two of our member companies, DesignMedix and RevMedx. Biotechnology Innovation Organization (BIO) had a strong turnout with representatives from over 41 states and more than 200 biotechnology and life science industry leaders from across the U.S. attended in the District of Columbia. Oregon Bio met with Members of Congress and staff to discuss our key legislative priorities. In meeting with our Congressional representatives and staff, one of our key messages was to ensure that the next generation of biotechnology breakthroughs get to the people who need them most. Our lawmakers have a role to play in supporting policies that foster innovation and encourage the entrepreneurial spirit and that address patient access to therapies, treatments and cures. Oregon Congressional delegates and their staff heard how the ability to innovate had made it possible for DesignMedix to offer a solution to treat malaria where other drugs are failing - a solution that is expected to be made available in areas of need for less than $1 a dose. They also got to see the XSTAT, a RevMedx product in use on the battlefield and among first responders statewide, in action. Members of the BIO Board of Directors from innovative biotechnology companies both big and [...]
About Michaele ArmstrongThis author has not yet filled in any details.
So far Michaele Armstrong has created 3 blog entries.
Bozinovic comes from Biocom Institute to join the local bio organization as it turns 30 (Portland, Ore.) –The Oregon Bioscience Association’s Board of Directors announced today the selection of its new Executive Director, Liisa Bozinovic, who will assume leadership of the trade/industry association on April 11, 2019. Bozinovic comes to Oregon’s growing life science and medical device industry organization from its peer organization, Biocom, where she currently serves as executive director of Biocom Institute. Biocom works to accelerate the success of its more than 1,100 members through advocacy, networking, capital development and purchasing programs. Biocom Institute provides a rich array of professional and workforce development and STEM education programs for the life science industry. Bozinovic has served in a variety of financial and operational leadership roles for Biocom over the years. Since 2014, she has served as the executive director of Biocom Institute. Previously, she spent four years in a financial and operational leadership position with Polyzen Inc., a developer and contract manufacturer of medical devices. Bozinovic is a proven leader and innovative thinker with broad-based expertise in operations, financial management, community relationship building, and value-driven program creation. Bozinovic also focused her time at Biocom Institute developing successful life science programming [...]
By Elizabeth Hayes – Staff Reporter, Portland Business Journal Mar 7, 2019, 3:29pm EST Eugene-based NemaMetrix, a biotech company that developed DNA testing equipment using nematode worms, has raised another $5 million, according to a filing with the U.S. Securities and Exchange Commission. Oregon Venture Fund was the lead investor and Rogue Venture Partners also participated, said NemaMetrix CEO Matt Beaudet. This is the company’s fourth funding round, bringing the grand total to $8.5 million. NemaMetrix has also garnered $4.5 million in grant funding from the National Institutes of Health and other entities and is currently making enough in revenue to “come close to sustaining” its operations, Beaudet said. NemaMetrix puts genetic material from patients with inherited diseases inside microscopic animals to determine the diseases' nature and hone potential future therapies. The process takes about three months. To this point, NemaMetrix's products have mostly helped basic research in labs, not clinical settings. That may soon change with this latest investment. “This acceleration will allow us to drive time down to 10 days, and that puts it in a time frame that allows it to be usable to give a clinician information to make a decision to treat an individual patient,” Beaudet [...]